Cytogen Inc
217330
Company Profile
Business description
Cytogen Inc is a Korea based company engaged in developing HD Microporous chip using microfluidics and nanotechnology and it captures viable CTCS (circulating tumor cells) from cancer patients blood. The firm operates in two business areas including Liquid Biopsy Applications and Liquid Biopsy Platforms. Its services and products include: cancer drug development and monitoring, companion diagnostics, clinical research, CLIA-certified services, preclinical xenograft models, and liquid biopsy equipment.
Contact
128, Beobwon-ro
8th floor, Building A
Munjeong-dong, Munjeong SK V1
Songpa-gu
Seoul05854
KORT: +82 269251070
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
45
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,882.60 | 20.50 | -0.23% |
| CAC 40 | 8,173.11 | 85.15 | -1.03% |
| DAX 40 | 25,184.89 | 204.21 | -0.80% |
| Dow JONES (US) | 50,382.83 | 196.87 | -0.39% |
| FTSE 100 | 10,491.39 | 25.13 | 0.24% |
| HKSE | 25,599.45 | 6.58 | -0.03% |
| NASDAQ | 26,583.85 | 239.88 | 0.91% |
| Nikkei 225 | 64,996.09 | 162.10 | -0.25% |
| NZX 50 Index | 13,069.74 | 99.46 | 0.77% |
| S&P 500 | 7,508.05 | 34.58 | 0.46% |
| S&P/ASX 200 | 8,657.80 | 18.80 | -0.22% |
| SSE Composite Index | 4,145.37 | 7.20 | -0.17% |